利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

419 条记录 (耗时 0.052 秒)

    Radioactive Halogen-Labeled Phenyloxyaniline Derivatives
    32.
    发明申请
    Radioactive Halogen-Labeled Phenyloxyaniline Derivatives 审中-公开
    放射性卤素标记苯氧基苯胺衍生物

    公开(公告)号：US20090234162A1

    公开(公告)日：2009-09-17

    申请号：US11884763

    申请日：2005-12-28

    申请人： Kazutoshi Suzuki ,  Tetsuya Suhara ,  Christer Halldin ,  Ming-Rong Zhang ,  Atsuro Nakazato

    发明人： Kazutoshi Suzuki ,  Tetsuya Suhara ,  Christer Halldin ,  Ming-Rong Zhang ,  Atsuro Nakazato

    IPC分类号： C07C233/25

    CPC分类号： A61K51/04 ,  C07B59/001 ,  C07B2200/05 ,  C07C233/88

    摘要： A radioactive halogen-labeled phenyoxyaniline derivative represented by the following formula: wherein R1 represents a group such as an alkyl group; X1, X2, X3 and X4 represent each a hydrogen atom, an alkyl group, an alkoxy group, an alkoxy group carrying 11C introduced thereinto or a radioactive halogen atom, provided that at least one of X1, X2, X3 and X4 represents an alkoxy group carrying 11C introduced thereinto or a radioactive halogen atom; which is a compound useful as a PBR ligand having a high affinity and a high selectivity. In in vitro measurement of PBR, a PBR ligand having a high affinity and a high selectivity is labeled with a radioactive halogen nuclear species so as to enable the measurement of PBR in vivo with the use of means including not only PET but also SPECT. Thus, a compound which is useful in early diagnosing, preventing and treating diseases such as Alzheimer type dementia can be obtained.

    摘要翻译： 由下式表示的放射性卤素标记的苯氧基苯胺衍生物：其中R1表示烷基等基团; X 1，X 2，X 3和X 4各自表示氢原子，烷基，烷氧基，带有11C的烷氧基或放射性卤素原子，条件是X 1，X 2，X 3和X 4中的至少一个表示烷氧基 携带11C的基团或放射性卤素原子; 其是可用作具有高亲和力和高选择性的PBR配体的化合物。 在PBR的体外测量中，具有高亲和力和高选择性的PBR配体用放射性卤素核物种进行标记，以便能够使用不仅包括PET而且还包括SPECT的方法在体内测量PBR。 因此，可以获得可用于早期诊断，预防和治疗诸如阿尔茨海默氏型痴呆症的疾病的化合物。

    Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
    33.
    发明授权
    Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists 失效
    取代的噻吩并[3,2-d]嘧啶作为CRF受体拮抗剂

    公开(公告)号：US07557111B2

    公开(公告)日：2009-07-07

    申请号：US10584951

    申请日：2005-01-06

    申请人： Atsuro Nakazato ,  Taketoshi Okubo ,  Dai Nozawa ,  Tomoko Tamita ,  Ludo E. J. Kennis

    发明人： Atsuro Nakazato ,  Taketoshi Okubo ,  Dai Nozawa ,  Tomoko Tamita ,  Ludo E. J. Kennis

    IPC分类号： C07D495/04 ,  A61K31/519

    CPC分类号： C07D495/04

    摘要： An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc.A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

    摘要翻译： 本发明的目的是提供一种抗CRF受体的拮抗剂，其作为治疗或预防药物是有效的，其涉及CRF被认为涉及的疾病，例如抑郁症，焦虑症，阿尔茨海默氏病，帕金森病，亨廷顿氏舞蹈病，进食 疾病，高血压，胃疾病，药物依赖，癫痫，脑梗塞，脑缺血，脑水肿，头部外伤，炎症，免疫相关疾病，特异性，肠易激综合征，睡眠障碍，癫痫，皮肤病，精神分裂症等。 由下式[I]表示的环状氨基取代的噻吩并嘧啶或噻吩并吡啶衍生物对CRF受体具有高亲和力，对于认为涉及CRF的疾病有效。

    DRUG FOR INHIBITING VASCULAR INTIMAL HYPERPLASIA
    34.
    发明申请
    DRUG FOR INHIBITING VASCULAR INTIMAL HYPERPLASIA 审中-公开
    用于抑制血管紧张素血症的药物

    公开(公告)号：US20090155187A1

    公开(公告)日：2009-06-18

    申请号：US12353646

    申请日：2009-01-14

    申请人： Hiroshi Nishiyama ,  Norimasa Shudo ,  Nobutomo Tsuruzoe

    发明人： Hiroshi Nishiyama ,  Norimasa Shudo ,  Nobutomo Tsuruzoe

    IPC分类号： A61K9/12 ,  A61K31/501

    CPC分类号： A61K31/501 ,  C07D237/14

    摘要： To provide an intimal hyperplasia inhibitor useful for prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) or vascular stent placement or treatment of its progress.An intimal hyperplasia inhibitor containing a 3(2H)-pyridazinone compound represented by the formula (I): [wherein each of R1, R2 and R3 is independently a hydrogen atom or a C1-6 alkyl group, X is a halogen atom, cyano or a hydrogen atom, Y is a halogen atom, trifluoromethyl or a hydrogen atom, and A is a C1-8 alkylene which may be substituted with a hydroxyl group] or a pharmacologically acceptable salt thereof.

    摘要翻译： 提供内皮增生抑制剂，可用于预防经皮腔内冠状动脉成形术（PTCA）或血管支架置入或治疗其进展后的再狭窄。 含有由式（I）表示的3（2H） - 哒嗪酮化合物的内膜增生抑制剂：其中R 1，R 2和R 3各自独立地为氢原子或C 1-6烷基，X为卤素原子，氰基 或氢原子，Y为卤素原子，三氟甲基或氢原子，A为可被羟基取代的C 1-8亚烷基]或其​​药理学上可接受的盐。

    THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP
    36.
    发明申请
    THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP 审中-公开
    用环状氨基取代的三烯酰基嘧啶和三烯吡啶衍生物

    公开(公告)号：US20090111835A1

    公开(公告)日：2009-04-30

    申请号：US12338698

    申请日：2008-12-18

    申请人： Atsuro Nakazato ,  Taketoshi Okubo ,  Dai Nozawa ,  Tomoko Tamita ,  Ludo E.J. Kennis

    发明人： Atsuro Nakazato ,  Taketoshi Okubo ,  Dai Nozawa ,  Tomoko Tamita ,  Ludo E.J. Kennis

    IPC分类号： A61K31/519 ,  C07D495/04 ,  A61K31/4365

    CPC分类号： C07D495/04

    摘要： An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

    摘要翻译： 本发明的目的是提供一种抗CRF受体的拮抗剂，其作为治疗或预防药物是有效的，其涉及CRF被认为涉及的疾病，例如抑郁症，焦虑症，阿尔茨海默氏病，帕金森病，亨廷顿氏舞蹈病，进食 疾病，高血压，胃疾病，药物依赖，癫痫，脑梗塞，脑缺血，脑水肿，头部外伤，炎症，免疫相关疾病，特异性，肠易激综合征，睡眠障碍，皮肤病，精神分裂症，疼痛等。 由下式[I]表示的环状氨基取代的噻吩并嘧啶或噻吩并吡啶衍生物对CRF受体具有高亲和力，对于认为涉及CRF的疾病有效。

    CLARITHROMYCIN OR SALT THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF PULMONARY DISEASE INDUCED BY DESTRUCTION OF PULMONARY ALVEOLI
    37.
    发明申请
    CLARITHROMYCIN OR SALT THEREOF FOR USE IN THE TREATMENT OR PREVENTION OF PULMONARY DISEASE INDUCED BY DESTRUCTION OF PULMONARY ALVEOLI 有权
    用于治疗或预防由破坏性血液病引起的肺部疾病的雷帕霉素或其盐

    公开(公告)号：US20090088395A1

    公开(公告)日：2009-04-02

    申请号：US11917845

    申请日：2006-06-21

    申请人： Kiyoshi Takayama

    发明人： Kiyoshi Takayama

    IPC分类号： A61K31/7028 ,  C07H17/08

    CPC分类号： A61K31/7048

    摘要： For the purpose of treatment and/or prevention of pulmonary disorders caused by the destruction of pulmonary alveoli resulting from smoking, air pollution, noxious gas, etc., there are provided, among others, a method of administering clarithromycin or a salt thereof to a mammal and a pharmaceutical composition comprising clarithromycin or a salt thereof.

    摘要翻译： 为了治疗和/或预防由吸烟，空气污染，有害气体等引起的肺泡破坏引起的肺部疾病的目的，提供了将克拉霉素或其盐施用于 哺乳动物和包含克拉霉素或其盐的药物组合物。

    MACROLIDE DERIVATIVES
    38.
    发明申请
    MACROLIDE DERIVATIVES 失效
    麦角糖衍生物

    公开(公告)号：US20090076253A1

    公开(公告)日：2009-03-19

    申请号：US12299229

    申请日：2007-05-01

    申请人： Masato Kashimura ,  Madoka Kawamura ,  Toshifumi Asaka ,  Kiyoshi Takayama ,  Haruhisa Ogita

    发明人： Masato Kashimura ,  Madoka Kawamura ,  Toshifumi Asaka ,  Kiyoshi Takayama ,  Haruhisa Ogita

    IPC分类号： C07H17/08

    CPC分类号： C07H17/08 ,  A61K31/7048 ,  A61K31/7052 ,  C07H17/00

    摘要： Compounds represented by formula (I) and the formula (IV) have an inhibitory activity of MMP-9 production, therefore, are useful as a medicine agent with fewer side effects than conventional MMP enzyme activity inhibitors, as a prophylactic and therapeutic drug for oncogenic angiogenesis, chronic rheumatoid arthritis, vascular intimal thickening after a percutaneous coronary transluminal angioplasty, vascular atherosclerosis, hemorrhagic apoplexy, acute myocardial infarction, chronic heart failure, aneurysm, lung cancer metastasis, adult respiratory distress syndrome, asthma, interstitial pulmonary fibrosis, chronic rhinosinusitis, bronchitis or chronic obstructive pulmonary disease (COPD).

    摘要翻译： 由式（I）和式（IV）表示的化合物具有抑制MMP-9产生的活性，因此作为一种具有比常规MMP酶活性抑制剂更少副作用的药剂可用作致癌剂的预防和治疗药物 血管生成，慢性类风湿关节炎，经皮冠状动脉腔内血管成形术后血管内膜增厚，血管动脉粥样硬化，出血性中风，急性心肌梗塞，慢性心力衰竭，动脉瘤，肺癌转移，成人呼吸窘迫综合征，哮喘，间质性肺纤维化，慢性鼻鼻窦炎， 支气管炎或慢性阻塞性肺疾病（COPD）。

    Method for assigning job in parallel processing method and parallel processing method
    40.
    发明授权
    Method for assigning job in parallel processing method and parallel processing method 失效
    并行处理方法和并行处理方法分配作业的方法

    公开(公告)号：US07370328B2

    公开(公告)日：2008-05-06

    申请号：US10257913

    申请日：2002-04-25

    申请人： Sou Yamada ,  Shinjiro Inabata ,  Nobuaki Miyakawa ,  Hajime Takashima ,  Kunihiro Kitamura ,  Unpei Nagashima

    发明人： Sou Yamada ,  Shinjiro Inabata ,  Nobuaki Miyakawa ,  Hajime Takashima ,  Kunihiro Kitamura ,  Unpei Nagashima

    IPC分类号： G06F9/44 ,  G06F15/16 ,  G06F15/163

    CPC分类号： G06F9/5066 ,  G06F9/4881

    摘要： When parallel processing is executed by parallel computers composed of a host computer and a plurality of processors connected to the host computer through a common bus, there is provided a method of assigning jobs to respective processors with high efficiency. A job in which a ratio between a communication time and a calculation time is larger than a predetermined value or larger than a fraction of processors and a job in which a ratio between a communication time and a calculation time is smaller than a predetermined value or smaller than a fraction of processors can be alternately assigned to respective processors. Alternatively, jobs are assigned to respective processors in such a manner that a plurality of processors and a plurality of jobs are divided into a plurality of groups in a one-to-one relation, jobs in which sizes comprising communication time and calculation time and ratios between the communication times and the calculation times approximate to each other may belong to different job groups and the order in which the jobs in which the sizes comprising the communication time and the calculation time and the ratios between the communication times and the calculation times approximate to each other are assigned within respective job groups may differ from each other among a plurality of job groups.

    摘要翻译： 当并行处理由主计算机和通过公共总线连接到主计算机的多个处理器组成的并行计算机执行时，提供了一种以高效率将作业分配给各个处理器的方法。 其中通信时间和计算时间之间的比率大于预定值或大于处理器的一部分的工作，以及通信时间和计算时间之间的比率小于预定值或更小的作业 可以将一小部分处理器交替分配给相应的处理器。 或者，将作业分配给各个处理器，使得多个处理器和多个作业以一对一的关系被分成多个组，其中包括通信时间和计算时间和比率的尺寸的作业 在通信时间和彼此近似的计算时间之间可以属于不同的作业组，并且其中包括通信时间和计算时间的尺寸以及通信时间与计算时间之间的比率近似于 彼此分配在各个作业组中可以在多个作业组中彼此不同。